4Moving Biotech, a subsidiary of 4P-Pharma, announces establishing an international Scientific Advisory Board in anticipation of its knee osteoarthritis drug candidate’s phase 2b clinical trial.
This board, composed of eminent international experts, will play a key role in supporting the development of 4P004, our drug candidate, to address the current gap in curative treatment for knee osteoarthritis.
The expertise of this committee will reinforce our scientific approach based on intraarticular GLP-1 analogs and will advise us on the best regulatory path.
Professor Francis Berenbaum, CMO of 4Moving Biotech, will lead the work of this scientific advisory board.
He will be joined by renowned medical experts, including:
- Philip Conaghan: Professor of Musculoskeletal Medicine, University of Leeds and Director, NIHR Leeds Biomedical Research Centre, United Kingdom.
- Felix Eckstein: Head of the Department for Imaging and Functional Musculoskeletal Research, Institute of Anatomy and Cell Biology, Paracelsus Medical University, Salzburg, Austria, and Chondrometrics GmbH, Freilassing.
- Ali Guermazi: Professor of Radiology and Medicine at Boston University School of Medicine, Boston, United States.
- Changqing Zhang: Director of the National Center for Orthopedics, Head of the Department of Orthopedic Surgery at the Sixth People’s Hospital, Director of Shanghai Institute of Microsurgery, Shanghai, China. He will be supported by Yanyan Song: Associate Professor in the Department of Biostatistics at the Institute of Clinical Research, Faculty of Medicine, Jiao-Tong University and Hongyi ZHU: Specialized Orthopedic Surgeon and Microsurgeon.
The Scientific Advisory Board will bring deep knowledge and experience from clinical research, academia, and industry to better serve people suffering from knee osteoarthritis.
Source link : https://www.businesswire.com/
